Shopping Cart
- Remove All
- Your shopping cart is currently empty
NVX-207 is a derivative of betulinic acid. It has anti-cancer activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $523 | 6-8 weeks | |
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | NVX-207 is a derivative of betulinic acid. It has anti-cancer activity. |
In vitro | NVX-207 decreases cell death via apoptosis. NVX-207 has high cytotoxicity (IC50: ranging from 7.6-8.5 μM), in the three analyzed malignant glioma cell lines. NVX-207 leads to PARP cleavage and to a decrease in Survivin expression levels under normoxic and hypoxic conditions. NVX-207 displays anti-tumor activity (mean IC50 = 3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7, and of poly (ADP-ribose) polymerase (PARP). NVX-207 (20 μM) induces a significantly high rate of necrosis of glioma cell lines[1][2]. |
In vivo | The intravenous application of NVX-207 is well tolerated in mice[1]. |
Molecular Weight | 601.86 |
Formula | C36H59NO6 |
Cas No. | 745020-66-0 |
Relative Density. | 1.14 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (207.69 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.